ABLEXIS LLC has a total of 64 patent applications. It decreased the IP activity by 90.0%. Its first patent ever was published in 2008. It filed its patents most often in United States, Republic of Korea and EPO (European Patent Office). Its main competitors in its focus markets biotechnology, agriculture and pharmaceuticals are KYMAB LTD, CRESCENDO BIOLOG LTD and EVROGEN IP.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 25 | |
#2 | Republic of Korea | 10 | |
#3 | EPO (European Patent Office) | 8 | |
#4 | Australia | 6 | |
#5 | Canada | 6 | |
#6 | New Zealand | 4 | |
#7 | WIPO (World Intellectual Property Organization) | 4 | |
#8 | Hong Kong | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Agriculture | |
#3 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Microorganisms | |
#3 | Animal care | |
#4 | Medical preparations |
# | Name | Total Patents |
---|---|---|
#1 | Green Larry | 54 |
#2 | Shizuya Hiroaki | 53 |
#3 | Duey Dana | 11 |
#4 | Lippincott John | 11 |
#5 | Singh Manish | 2 |
#6 | Roh Cecilia | 2 |
Publication | Filing date | Title |
---|---|---|
US2019292258A1 | Anti-cd47 antibodies | |
US2018258175A1 | Anti-CD115 antibodies | |
AU2015200339A1 | Method of generating single VL domain antibodies in transgenic animals | |
CA2787498A1 | Genetic engineering of non-human animals for the production of chimeric antibodies | |
KR20190065477A | Non-human mammals for the production of chimeric antibodies | |
NZ589411A | Method of generating single vl domain antibodies in transgenic animals | |
NZ586149A | Methods for sequential replacement of targeted region by homologous recombination |